Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mymensingh Med J ; 29(1): 195-201, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31915358

RESUMEN

Gastric cancer (GC) is one of the most common tumors and remains the second leading cause of cancer mortality in the world. The incidence of gastric carcinoma is declining in the last few years in some areas like USA, UK, Canada etc, because of reduction in chronic H. pylori infection, smoking, decrease use of smoked and salted food. The gastric carcinoma still remains a burden for Bangladesh as the prevalence of H. Pylori has not substantially decreases. Among the gastric carcinomas, adenocarcinomas are the most common type. So the study was performed to observe the location and histomorphologic pattern of Gastric and gastrooesophageal junction (GEJ) adenocarcinoma. This descriptive cross sectional study was carried out at the Department of Pathology, Dhaka Medical College, Dhaka, Bangladesh from January 2013 to December 2014. A total of 130 patients with primary gastric and GEJ adenocarcinomas were included in this study. All the cases were evaluated for routine histological examination. The age range of the patients was 17 to 80 years and male to female ratio was 2.25:1. Antrum is the most common (66.9%) site being affected, followed by GEJ (19.2%), body (13%) and fundus (0.76%). Tumors of the antrum and GEJ were found mostly in the late age. On macroscopic examination, the ulcerated tumor mass (69.2%) was most frequent then the others. Regarding histological examination, 84(64.6%) cases were intestinal type, 32(24.6%) diffuse and 14(10.8%) mixed type by Laurens classification. According to WHO classification, about half of the cases (49.2%) were tubular carcinoma and rest were others. Most of the intestinal type carcinoma (71.4%) was presented with moderately differentiated and 25.0% with well differentiated. Where as the diffuse type presented with poorly differentiated in 96.9% cases.


Asunto(s)
Adenocarcinoma/patología , Unión Esofagogástrica/patología , Neoplasias Gástricas/patología , Adenocarcinoma/clasificación , Adenocarcinoma/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Bangladesh/epidemiología , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Gástricas/epidemiología , Adulto Joven
2.
Mymensingh Med J ; 27(3): 669-671, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30141463

RESUMEN

Steatocystoma is a benign adnexal tumor arising from the pilosebaceous duct junction. It can be classified into two groups (steatocystoma simplex and steatocystoma multiplex). Steatocystoma simplex, which presents as a solitary, non-herited very rare lesion in adult. It occurs most commonly in the axillae, in the sternal region and on the arms. Scalp is an extremely rare location. We report a case of 49-years-old male admitted in Department of Surgery, Dhaka Medical College & Hospital, Dhaka, Bangladesh on February 2017 presented with slowly progressing painless, soft, yellowish, single smooth surface mass on the left parietal scalp which had persisted for a period of 8 years. The histopathologic examination revealed a thin-walled cyst consisting of stratified squamous epithelium with lack of granular layer and containing sebaceous gland close to the wall. These findings were consistent with steatocystoma. At the 4-month follow-up, there was no sign of recurrence or development of the steatocystoma or any other masses.


Asunto(s)
Quiste Epidérmico , Neoplasias Cutáneas , Adulto , Bangladesh , Quiste Epidérmico/diagnóstico , Quiste Epidérmico/cirugía , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Cuero Cabelludo , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/cirugía
3.
Mymensingh Med J ; 26(2): 372-379, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-28588175

RESUMEN

Gastric carcinoma is a biologically heterogenous disease and survival varies among the patients with same stage. Recent studies have shown that a subset of gastric and gastroesophageal junction adenocarcinoma over express the HER2/neu protein and these patients can be treated by monoclonal antibody against HER2/neu protein. The purpose of this study was to detect the frequency of HER2 expression in gastric and gastroesophageal junction adenocarcinoma and to evaluate the relationship between HER2 expression and clinicopathological features in these patients. This descriptive cross sectional study was carried out at the Department of Pathology, Dhaka Medical College, from January 2013 to December 2014. A total of 130 patients with primary gastric and gastroesophageal junction adenocarcinomas were included in this study. All the cases were evaluated for routine histological examination and immunohistochemical examination was done for HER2/neu protein. Among the 130 cases, HER2 over expression was found in 12.3% cases and was more frequent in gastroesophageal junction (28%) than in gastric carcinoma (8.6%) (P=0.026). HER2 positivity was found significantly more in intestinal type carcinoma (19%), papillary carcinoma (63%) and in fungating growth pattern (P=0.003, 0.001 and 0.001 respectively). HER2 expression was also positive in grade-I or grade-II tumor but negative in grade-III tumor (P=0.001). No significant association of HER2 expression was found with age, sex, lymph node metastasis and extent of tumor. In conclusion it can be stated that gastric and gastroesophageal junction adenocarcinoma of intestinal type or papillary and tubular type with well to moderate differentiation can be targeted for therapy using Herceptin.


Asunto(s)
Adenocarcinoma , Receptor ErbB-2 , Neoplasias Gástricas , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/metabolismo , Bangladesh , Estudios Transversales , Unión Esofagogástrica/metabolismo , Humanos , Receptor ErbB-2/metabolismo , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/metabolismo , Trastuzumab/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...